脂蛋白相关磷脂酶A2在急性冠状动脉综合征中作用的研究进展

doi:10.16352/j.issn.1001-6325.2024.01.0103

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (1): 103-107.doi: 10.16352/j.issn.1001-6325.2024.01.0103

脂蛋白相关磷脂酶A2在急性冠状动脉综合征中作用的研究进展

郭健宏, 王亚玲^*, 崔文光

河北北方学院附属第一医院心血管内科,河北张家口 075000

收稿日期:2023-04-07 修回日期:2023-09-26 出版日期:2024-01-05 发布日期:2023-12-25
通讯作者: ^*:1907577068@qq.com
基金资助:
张家口市科学技术研究与发展计划(1911021D-1)

Research progress on the role of lipoprotein- associated phospholipase A2 in acute coronary syndrome

GUO Jianhong, WANG Yaling^*, CUI Wenguang

Department of Cardiovascular Medicine, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000,China

Received:2023-04-07 Revised:2023-09-26 Online:2024-01-05 Published:2023-12-25
Contact: ^*:1907577068@qq.com

摘要/Abstract

摘要： 脂蛋白相关磷脂酶A2(Lp-PLA2)是一种由441个氨基酸组成的蛋白。Lp-PLA2能够促进炎细胞向炎性反应部位聚集及炎性因子的释放,促进基质金属蛋白酶的合成,使动脉粥样硬化斑块内泡沫细胞及细胞外基质增多,并且使斑块纤维帽变薄而易于破裂,进而促进急性冠脉综合征(ACS)的发病。因此在急性冠脉综合征患者中测定和调节Lp-PLA2水平具有重要的临床意义。

关键词: 脂蛋白相关磷脂酶A2, 急性冠脉综合征, 动脉粥样硬化

Abstract: Lipoprotein-associated phospholipase A2(Lp-PLA2) is a protein composed of 441 amino acids, which can promote the aggregation of inflammatory cells to the inflammatory response site and the release of inflammatory factors. It can promote the synthesis of matrix metalloproteinases, increase the number of foam cells and extra cellular matrix in atherosclerotic plaque, attenuate plaque fiber cap and prone to rupture, thus promote the onset of acute coronary syndrome(ACS). Therefore, the determination and regulation of Lp-PLA2 levels in patients with ACS are clinically significant.

Key words: lipoprotein-associated phospholipase A2, acute coronary syndrome, atherosclerosis

中图分类号:

R541.4

郭健宏, 王亚玲, 崔文光. 脂蛋白相关磷脂酶A2在急性冠状动脉综合征中作用的研究进展[J]. 基础医学与临床, 2024, 44(1): 103-107.

GUO Jianhong, WANG Yaling, CUI Wenguang. Research progress on the role of lipoprotein- associated phospholipase A2 in acute coronary syndrome[J]. Basic & Clinical Medicine, 2024, 44(1): 103-107.

参考文献 25

[1]	Ma S, Ding L, Cai M, et al. Association Lp-PLA2 gene polymorphisms with coronary heart disease[J]. Dis Markers, 2022, 2022: 9775699. doi: 10.1155/2022/9775699. eCollection 2022.
[2]	Zhuo S, Yuan C. Active site competition is the mechanism for the inhibition of lipoprotein-associated phospholipase A(2) by detergent micelles or lipoproteins and for the efficacy reduction of darapladib[J]. Sci Rep, 2020, 10: 17232. doi: 10.1038/s41598-020-74236-0.
[3]	Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Purification and properties[J]. J Biol Chem, 1987, 262: 4223-4230.
[4]	Wojcicka G, Zareba M, Warpas A, et al. The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydro-lase (PAF-AH) activity and concentration in normal and fructose-fed rats[J]. Eur J Pharmacol, 2019, 850:180-189. doi: 10.1016/j.ejphar.2019.02.014.
[5]	Lv SL, Zeng ZF, Gan WQ, et al. Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation[J]. Acta Pharmacol Sin, 2021, 42: 2016-2032. doi: 10.1038/s41401-021-00703-7.
[6]	Kim SR, Heo JI, Park JW, et al. Radiation-induced lipoprotein-associated phospholipase A2 increases lysophosphatidylcholine and induces endothelial cell damage[J]. Toxicology, 2021, 458: 152841. doi: 10.1016/j.tox.2021.152841.
[7]	Mourouzis K, Siasos G, Oikonomou E, et al. Lipoprotein-associated phospholipase A2 levels, endothelial dysfunc-tion and arterial stiffness in patients with stable coronary artery disease[J]. Lipids Health Dis, 2021, 20: 12. doi: 10.1186/s12944-021-01438-4.
[8]	Hu HJ, Qiu J, Zhang C, et al. Hydrogen sulfide improves ox-LDL-induced expression levels of Lp-PLA(2) in THP-1 monocytes via the p38MAPK pathway[J]. Mol Med Rep, 2021, 23: 358. doi: 10.3892/mmr.2021.11997.
[9]	刘琴, 杨黎星, 石婧, 等. 小檗碱激活巨噬细胞自噬并改善动脉粥样硬化斑块脆弱性[J].基础医学与临床, 2020, 40: 668-677.
[10]	Zhang H, Zhou W, Cao C, et al. Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40[J]. PLoS One, 2018, 13: e0202797. doi: 10.1371/journal.pone.0202797.
[11]	Chandra S, Nagar S, Shukla A, et al. Correlation of lipoprotein (a) levels and plaque morphology in very young acute coronary syndrome patients using optical coherence tomography[J]. Indian Heart J, 2022, 74: 357-362. doi: 10.1016/j.ihj.2022.09.001.
[12]	陈四华, 孙旭晖, 袁强. 血清高敏 C 反应蛋白、脂蛋白相关磷脂酶 A2 水平与高血压合并冠状动脉粥样硬化性心脏病患者冠状动脉罪犯血管纤维脂质斑块纤维帽厚度的相关性[J]. 中华高血压杂志, 2020, 28: 676-679.
[13]	Meng PN, Yin DL, Lu WQ, et al. Intensive statin versus low-dose statin + ezetimibe treatment for fibrous cap thickness of coronary vulnerable plaques[J]. Chin Med J (Engl), 2020, 133: 2415-2421.
[14]	张显敏, 梁琳. 血浆脂联素、脂蛋白相关磷脂酶 A2 检测联合颈动脉超声检查对冠状动脉易损斑块的诊断价值[J]. 陕西医学杂志, 2022, 51: 713-716.
[15]	Zhang L, Li Z, Li N. Serum IMA and LP-PLA2 levels in patients with coronary heart disease and their correlation with the degree of myocardial ischaemia and their diagnostic value[J]. Emerg Med Int, 2022, 2022: 1698315.doi:10.1155/2022/1698315.
[16]	Yang F, Ma L, Zhang L, et al. Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study[J]. Heart Vessels, 2019, 34: 1608-1614.
[17]	Wang R, Wang X, Zhang E, et al. Correlation of plasma galectin-3 and plasma lipoprotein-associated phospholipase A2 with the severity and prognosis of coronary artery disease [J]. Am J Transl Res, 2021, 13: 8997-9004.
[18]	李爱华, 张社兵, 徐新, 等. 血清缺血修饰白蛋白、内皮糖蛋白和脂蛋白相关磷脂酶A2表达特征与急性冠状动脉综合征患者危险分层相关性[J]. 临床军医杂志, 2021, 49: 1152-1154.
[19]	叶斐, 王腾, 于宗良. 阿托伐他汀联合依折麦布对急性冠状动脉综合征患者白细胞分化抗原40配体、脂蛋白相关磷脂酶A2和心功能的影响[J]. 心脑血管病防治, 2022, 22: 37-40.
[20]	Qian K, Chen Q, Ding H, et al. Effects of Danhong injection combined with tirofiban on cardiac function, myocardial enzyme spectrum and lipoprotein-associated phospholipase A2 level in patients with acute myocardial infarction[J]. Am J Transl Res. 2022, 14: 7951-7959.
[21]	Baziar N, Nasli-Esfahani E, Djafarian K, et al. The beneficial effects of alpha lipoic acid supplementation on Lp-PLA2 mass and its distribution between HDL and apoB-containing lipoproteins in type 2 diabetic patients: a randomized, double-blind, placebo-controlled trial[J]. Oxid Med Cell Longev, 2020, 2020: 5850865. doi: 10.1155/2020/5850865.
[22]	谢杰, 李拥军. 急性心肌梗死病人血清PLA2和Hcy水平与心室重构的关系[J]. 中西医结合心脑血管病杂志, 2021, 19: 4120-4123.
[23]	刘佳良, 郭黎平, 乔举伟. 血清LP-PLA2、MCP-1水平与ST段抬高型心肌梗死患者PCI后心力衰竭发生的关系[J]. 医药论坛杂志, 2022, 43: 80-82.
[24]	Sheng G, Zhou J, Zhang C, et al. Relationship between Lp-PLA2 and in-stent restenosis after coronary stenting: a 3-year follow-up study[J]. Scott Med J, 2021, 66: 178-185.
[25]	Norata GD, Woudstra P, Damman P, et al. Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction[J]. PLoS One, 2014, 9: e96251.doi: 10.1371/journal.pone.0096251.

脂蛋白相关磷脂酶A2在急性冠状动脉综合征中作用的研究进展

Research progress on the role of lipoprotein- associated phospholipase A2 in acute coronary syndrome

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈林木, 黄云秀. 壳寡糖上调SRBI核心岩藻糖基化修饰水平减弱小鼠动脉粥样硬化斑块形成[J]. 基础医学与临床, 2024, 44(4): 474-482.
[2]	余晗俏, 李超, 余育斌, 冯丽娜, 盛晓生, 叶晓霞, 王林燕. 抑制髓样细胞触发受体-1(TREM-1)减轻慢性间歇性低氧诱发的模型小鼠动脉粥样硬化[J]. 基础医学与临床, 2024, 44(3): 368-373.
[3]	张秀丽, 胡孝刚, 莫俊, 陈铃. 冠心宁片减轻大鼠颈动脉粥样硬化斑块损伤[J]. 基础医学与临床, 2024, 44(2): 192-198.
[4]	宋星明, 哈力沙·艾日肯江, 迪丽胡玛尔·阿布来提, 高颖. 内皮脂肪酶作为冠心病治疗靶点的研究进展[J]. 基础医学与临床, 2023, 43(9): 1443-1447.
[5]	杜丰禾, 刘暴. 血管周围脂肪组织炎性反应促进动脉粥样硬化作用机制的研究进展[J]. 基础医学与临床, 2023, 43(4): 685-689.
[6]	刘怡斐, 王鑫宇, 王嘉慧, 杜晓冰, 王途, 赵娟. 尾加压素Ⅱ受体拮抗剂(urantide)减轻动脉粥样硬化大鼠肾脏损伤[J]. 基础医学与临床, 2023, 43(11): 1668-1672.
[7]	朱冰, 王旭. 斑点追踪成像技术在缺血性心脏病诊断中的应用[J]. 基础医学与临床, 2022, 42(9): 1459-1463.
[8]	刘珍竹, 李靖, 何丹, 曲鹏. PI3K信号通路调控动脉粥样硬化发生发展的研究进展[J]. 基础医学与临床, 2022, 42(9): 1428-1432.
[9]	赵茂宇, 李佑美, 刘焕云, 毛琦. 胰岛素抵抗标志物在动脉粥样硬化发病中的研究进展[J]. 基础医学与临床, 2022, 42(8): 1302-1305.
[10]	谢思安, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 刘思. VAV1是动脉粥样硬化预后的潜在靶点和生物标志物[J]. 基础医学与临床, 2022, 42(7): 1092-1098.
[11]	裘耀扬, 桂家辉, 黄林, 虎学强, 李勤. 血管内光学相干层析成像技术在冠状动脉粥样硬化斑块检测方面的应用[J]. 基础医学与临床, 2022, 42(3): 360-365.
[12]	张爽, 李之凡, 钱杰, 吴娜琼. 腔内影像学方法评价降脂治疗对冠状动脉粥样硬化斑块影响的研究进展[J]. 基础医学与临床, 2022, 42(3): 366-371.
[13]	张琦悦, 张伟丽. 血管老化在动脉粥样硬化中的研究进展[J]. 基础医学与临床, 2022, 42(3): 372-377.
[14]	赵川榕, 周菁. 靶向剪切力敏感关键分子的动脉粥样硬化防治研究[J]. 基础医学与临床, 2022, 42(3): 378-383.
[15]	李欢欢, 张玉齐, 吕海宏. 氧化应激增加多囊卵巢综合征患者心血管疾病风险的研究进展[J]. 基础医学与临床, 2022, 42(12): 1950-1954.